We are an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

Innovative medical equipment

We enable healthier lives, everywhere, every day

As the leader in women’s health, we deliver life-changing and life-saving diagnostic, detection, and surgical products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision, and ever-greater peace of mind.

About Us

Featured Products

picture of 3-Dimensions Mammography System

3Dimensions™ Mammography System
picture of Panther Fusion Assays

Panther Fusion® Assays
picture of Brevera Breast Biopsy System

Brevera® Breast Biopsy System
picture of Aptima Herpes Simplex 1&2 assay

Aptima® Herpes Simplex 1&2 assay

Affirm Prone Breast Biopsy System

Affirm® Prone Breast Biopsy System
picture of Horizon DXA System

Horizon® DXA System
picture of ThinPrep Pap test

ThinPrep® Pap test
picture of Fluoroscan InSight Mini C-arm Extremities Imaging System

Fluoroscan® InSight® Mini C-arm Extremities Imaging System
picture of Hologic SARS-CoV-2 Assays

Hologic SARS-CoV-2 Assays
picture of MyoSure Tissue Removal Suite

MyoSure® Tissue Removal Suite
picture of NovaSure Endometrial Ablation

NovaSure® Endometrial Ablation

Financial Fast Facts

Revenue Highlights 2Q23

Non-GAAP
Revenue ($M) 		2Q23 Reported ∆
Vs 2Q22 		CC ∆ Vs 2Q22
Diagnostics $464.7 (52.9%) (52.2%)
Organic Diagostics ex. COVID-1922 $355.0 13.0% 14.9%
Organic Molecular Diag. ex. COVID-19 $243.1 22.3% 23.9%
Breast Health $385.4 24.2% 25.7%
GYN Surgical $144.8 23.4% 25.2%
Skeletal Health $31.6 51.2% 53.4%
Total Revenue $1,026.5 (28.5%) (27.5%)
Organic Revenue2 $1,015.9 (28.8%) (27.7%)
Organic ex COVID-193 $916.8 20.2% 21.9%
US Revenue $768.7 (22.5%) -
Intl Revenue $257.8 (41.9%) (38.5%)

Financial Overview 2Q23

Non-GAAP
In Millions ex. EPS 		2Q23 ∆ vs. 2Q22
Revenue ($M) $1026.5 (28.5%)
Organic Revenue2 $1015.9 (28.8%)
Organic ex COVID-193 $916.8 20.2%
Gross Margin 62.1% (890) bps
Operating Expenses $317.0 (6.3%)
Operating Margin 31.3% (1,610) bps
Net Margin 25.9% (1,060) bps
Diluted EPS $1.06 (48.8%)
EBITDA $345.4 (50.9%)

Financial Guidance for Third Quarter Fiscal 2023

Non-GAAP 3Q23 Reported vs. 3Q22 CC vs. 3Q22 Organic4 vs. 3Q22
Revenue ($M) $930 - $980 (7.2%) to (2.3%) (6.9%) to (1.9%) (6.8%) to (1.8%)
Non-GAAP EPS $0.83 - $0.93 (12.6%) to (2.1%)
GAAP EPS $0.64 - $0.74 (28.9%) to (17.8%)

Financial Guidance for Full Fiscal 2023

Non-GAAP FY23 Reported vs. FY22 CC vs. FY22 Organic4 vs. FY22
Revenue ($M) $3,925 - $4,025 (19.3%) to (17.2%) (18.5%) to (16.4%) (18.7%) to (16.6%)
Non-GAAP EPS $3.75 - $3.95 (37.7%) to (34.4%)
GAAP EPS $2.91 - $3.11 (43.3%) to (39.4%)

Capital Deployment

Expect strong cash flow in fiscal second quarter and full year 2022

Business development priorities:

  • Tuck-in acquisitions
  • Accretive to revenue, EPS growth rates
  • Attractive ROIC
  • Leverage existing strengths

Net Debt & Leverage Ratio1

Revenue & CC Growth Rates

2022 Divisional Revenue by Geography

Non-GAAP EPS & Growth Rates

Adjusted Operating Cash Flow5

ROIC

  1. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
  2. Organic revenue excludes divestited Blood business.
  3. Total organic revenue excluding COVID-19.
  4. Organic revenue on a constant currency basis. Excludes the divested Blood business.
  5. Operating cash flow adjusted for one-time tax and litigation items.